Loading organizations...
Ci:z Investment operates as a global private investment firm, strategically deploying capital into promising startups across diverse sectors. It focuses on strategic equity investments, backing innovative companies with significant market disruption potential. The firm’s thesis supports ventures introducing transformative changes and advancing their respective industries.
The firm's foundation traces to Dr. Yoshinori Shirono, its Chief Executive Officer. A Keio University School of Medicine graduate, Dr. Shirono pioneered anti-aging and laser treatment in Japan, establishing the Ci:z medical clinic group. This entrepreneurial success led to Ci:z Holdings Co., Ltd., and subsequently Ci:z Investment LLP, reflecting an insight into fostering innovation through strategic capital deployment.
Ci:z Investment serves early and growth-stage startups globally, providing crucial expansion funding. The firm aims to contribute to global progress by empowering companies poised to redefine industries and solve complex challenges, fostering an ecosystem for groundbreaking ideas and societal advancements.
Ci:z Investment has 2 tracked investments across 2 companies. The latest tracked deal is $29.2M Series C in Fukushima SiC Applied Engineering in September 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 7, 2020 | Fukushima SiC Applied Engineering | $29.2M Series C | — | Astellas Venture Management, Japan Post Investment Corporation, SMBC Venture Capital |
| May 7, 2019 | Promethera Biosciences | $44.6M Series D | Shinsei Capital Partners | Cyril Janssen, Marc Speeckaert, Olivier VAN DER Rest, Korea Investment Partners, MEDIPAL HOLDINGS CORPORATION, Mirae Asset Capital, Mitsui & CO. Global Investment, SIX Snow |
